Pediatric clinical pharmacist in the role of therapeutic drug monitoring.doc

 PAGE \* MERGEFORMAT 4 Pediatric clinical pharmacist in the role of therapeutic drug monitoring Author: Gao Xuan, Zhang Xuhui, Cao Di, Zhi-Ping Li [Keywords:] therapeutic drug monitoring of pediatric clinical pharmacists Therapeutic drug monitoring (Therapeutic Drug Monitoring, TDM) in the last 30 years formed a branch of clinical medicine, but also clinical and pharmacological effects of drugs, drug interactions, toxicity of the relationship between the administration in order to develop individualized programs to improve patient compliance, improve clinical drug safety, efficacy and reduce the incidence of adverse reactions has become an important content of the work of clinical pharmacists. Pediatric patients, especially newborn and premature children, a variety of physiological functions, including self-regulatory function are not fully developed, more sensitive to drug response, and adults are very different, and therefore a greater need based on age, developmental level, overall health status reasonable individualized drug treatment. In our hospital since 1999 to adopt a principle of fluorescence polarization immunoassay for plasma concentrations of fast analyzer (TDx  FLx, the United States Abbot company) in our hospital and outpatient use of carbamazepine (Carbamazepine, CBZ), valproic acid (Valproate, VPA), digoxin (Digoxin, DIG), methotrexate (Methotrexate, MTX) and cyclosporine A (Cyclosporine A, CsA) in children with drugs such as blood concentration monitoring of clinical pharmacology and the plasma concentration of both measurement techniques are closely linked to my hospital rational use of medicines in children, formulation and adjustment of individualized medicine programs, drug poisoning first aid, to reduce adverse reactions and improve the treatment level has a positive meaning. Here’s our hospital pediatric clinical pharmacists TDM practice, analysis, and to explore ways to do this work. A way of taking the issue of drug VPA sustain